416 related articles for article (PubMed ID: 25433414)
1. Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.
Walter TC; Steffen IG; Stelter LH; Maurer MH; Bahra M; Faber W; Klein F; Bläker H; Hamm B; Denecke T; Grieser C
Eur Radiol; 2015 May; 25(5):1329-38. PubMed ID: 25433414
[TBL] [Abstract][Full Text] [Related]
2. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
[TBL] [Abstract][Full Text] [Related]
3. Validation of the 2012 International Consensus Guidelines Using Computed Tomography and Magnetic Resonance Imaging: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Seo N; Byun JH; Kim JH; Kim HJ; Lee SS; Song KB; Kim SC; Han DJ; Hong SM; Lee MG
Ann Surg; 2016 Mar; 263(3):557-64. PubMed ID: 25822687
[TBL] [Abstract][Full Text] [Related]
4. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
[TBL] [Abstract][Full Text] [Related]
5. Pre-operative nomogram predicting malignant potential in the patients with intraductal papillary mucinous neoplasm of the pancreas: focused on imaging features based on revised international guideline.
Hwang JA; Choi SY; Lee JE; Kim SS; Lee S; Moon JY; Heo NH
Eur Radiol; 2020 Jul; 30(7):3711-3722. PubMed ID: 32095876
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct.
Kang MJ; Jang JY; Lee S; Park T; Lee SY; Kim SW
World J Surg; 2015 Aug; 39(8):2006-13. PubMed ID: 25894399
[TBL] [Abstract][Full Text] [Related]
7. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
[TBL] [Abstract][Full Text] [Related]
8. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
9. CT and MR imaging of multilocular acinar cell cystadenoma: comparison with branch duct intraductal papillary mucinous neoplasia (IPMNs).
Delavaud C; d'Assignies G; Cros J; Ruszniewski P; Hammel P; Levy P; Couvelard A; Sauvanet A; Dokmak S; Vilgrain V; Vullierme MP
Eur Radiol; 2014 Sep; 24(9):2128-36. PubMed ID: 24895037
[TBL] [Abstract][Full Text] [Related]
10. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN).
Das KK; Xiao H; Geng X; Fernandez-Del-Castillo C; Morales-Oyarvide V; Daglilar E; Forcione DG; Bounds BC; Brugge WR; Pitman MB; Mino-Kenudson M; Das KM
Gut; 2014 Oct; 63(10):1626-34. PubMed ID: 24277729
[TBL] [Abstract][Full Text] [Related]
11. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas.
Kobayashi N; Sugimori K; Shimamura T; Hosono K; Watanabe S; Kato S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A; Kubota K
Pancreatology; 2012; 12(2):141-5. PubMed ID: 22487524
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Malignancy in "Pure" Branch-Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas without Enhancing Mural Nodules on CT Imaging: A Nationwide Multicenter Study.
Kim TH; Woo YS; Chon HK; Hwang JH; Yoo KS; Lee WJ; Lee KH; Lee JK; Dong SH; Park CH; Park ET; Moon JH; Kim HG; Cho KB; Kim HJ; Lee SO; Cheon YK; Lee JM; Park JW; Kim MH
Gut Liver; 2018 Sep; 12(5):583-590. PubMed ID: 29730906
[TBL] [Abstract][Full Text] [Related]
14. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
15. Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography.
Harima H; Kaino S; Shinoda S; Kawano M; Suenaga S; Sakaida I
World J Gastroenterol; 2015 May; 21(20):6252-60. PubMed ID: 26034360
[TBL] [Abstract][Full Text] [Related]
16. Intraductal Papillary Mucinous Neoplasms of the Pancreas: Correlation of Helical Computed Tomography (CT) Features With Pathologic Findings.
Xu W; Liu X; Zhang J; Yang L
Acad Radiol; 2017 May; 24(5):609-614. PubMed ID: 28153575
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of intraductal papillary mucinous neoplasms of the pancreas on MDCT and MRI].
Wang D; Zhou J; Zheng S; Xia J; Hu H
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):682-7. PubMed ID: 25564059
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
[TBL] [Abstract][Full Text] [Related]
20. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
